Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors

The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2000-10, Vol.43 (20), p.3778-3785
Hauptverfasser: Mahadevan, Anu, Siegel, Craig, Martin, Billy R, Abood, Mary E, Beletskaya, Irina, Razdan, Raj K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3785
container_issue 20
container_start_page 3778
container_title Journal of medicinal chemistry
container_volume 43
creator Mahadevan, Anu
Siegel, Craig
Martin, Billy R
Abood, Mary E
Beletskaya, Irina
Razdan, Raj K
description The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3, and C-9 positions were chosen since these positions have played a key role in the SAR of THCs. CBN-3-(1‘,1‘-dimethylheptyl) analogues were prepared by sulfur dehydrogenation of Δ8-THC-3-(1‘,1‘-dimethylheptyl) analogues. 9-Substituted CBN analogues were prepared by the standard sulfur dehydrogenation of 9-substituted Δ8-THC analogues (Scheme ), which in turn were prepared following our previous procedure using selenium dioxide oxidation of the corresponding Δ8-THCs followed by sodium chlorite oxidation to give the 9-carboxy-Δ8-THC derivatives. 11-Hydroxy-CBN analogues were prepared from the corresponding 9-carbomethoxy-CBN analogues by reduction with LiAlH4. Deoxy-CBN analogue 14 was prepared from the corresponding Δ8-THC analogue 11 by conversion of the phenolic hydroxyl to the phosphate derivative 12, followed by lithium ammonia reduction to provide the deoxy-Δ8-THC analogue 13, which in turn was dehydrogenated with sulfur to provide the deoxy-CBN analogue 14 (Scheme ). The various analogues were assayed for binding both to the brain and the peripheral cannabinoid receptors (CB1 and CB2). We have found that the binding profile differs widely between the CBN and the THC series. Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced. Thus, in the CBN series, the selectivity of binding observed with the removal of the hydroxy group is decreased severalfold as compared to what occurs in the THC series. Generally, high affinity for the CB2 receptor was found in analogues when the phenolic hydroxyl was present. The 3-(1‘,1‘-dimethylheptyl) derivatives were found to have much higher affinities than the CBN analogues, which is in complete agreement with previously reported work by Rhee et al.
doi_str_mv 10.1021/jm0001572
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72321833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72321833</sourcerecordid><originalsourceid>FETCH-LOGICAL-a403t-fc0f2bdbb0734bb68b4d372e817f91ff762f65a6d548e5e1d1e9647ca91fe3023</originalsourceid><addsrcrecordid>eNpt0D1PwzAQBmALgWgpDPwBlAGQGAL22YnTgQFSvkQFBYqQWCw7saWUJC52i-DfY9SqXZhueJ87nV6E9gk-JRjI2aTBGJOEwwbqkgRwzDLMNlEXY4AYUqAdtOP9JCBKgG6jDglrGPq0i84f7Jeuo1y2rVRVa-to5KzSPjLWRfkliWRbhglrUZXRsy70dGad30VbRtZe7y1nD71eX43z23j4eHOXXwxjyTCdxabABlSpFOaUKZVmipWUg84IN31iDE_BpIlMy4RlOtGkJLqfMl7IEGqKgfbQ8eLu1NnPufYz0VS-0HUtW23nXnCgQDJKAzxZwMJZ7502YuqqRrofQbD460qsugr2YHl0rhpdruWynAAOl0D6QtbGybao_NolQFhCAosXrPIz_b2KpfsQKac8EePRi3ga0MHoHr-J9-CPFl4WXkzs3LWhun_--wXYMYjo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72321833</pqid></control><display><type>article</type><title>Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors</title><source>MEDLINE</source><source>American Chemical Society (ACS) Journals</source><creator>Mahadevan, Anu ; Siegel, Craig ; Martin, Billy R ; Abood, Mary E ; Beletskaya, Irina ; Razdan, Raj K</creator><creatorcontrib>Mahadevan, Anu ; Siegel, Craig ; Martin, Billy R ; Abood, Mary E ; Beletskaya, Irina ; Razdan, Raj K</creatorcontrib><description>The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3, and C-9 positions were chosen since these positions have played a key role in the SAR of THCs. CBN-3-(1‘,1‘-dimethylheptyl) analogues were prepared by sulfur dehydrogenation of Δ8-THC-3-(1‘,1‘-dimethylheptyl) analogues. 9-Substituted CBN analogues were prepared by the standard sulfur dehydrogenation of 9-substituted Δ8-THC analogues (Scheme ), which in turn were prepared following our previous procedure using selenium dioxide oxidation of the corresponding Δ8-THCs followed by sodium chlorite oxidation to give the 9-carboxy-Δ8-THC derivatives. 11-Hydroxy-CBN analogues were prepared from the corresponding 9-carbomethoxy-CBN analogues by reduction with LiAlH4. Deoxy-CBN analogue 14 was prepared from the corresponding Δ8-THC analogue 11 by conversion of the phenolic hydroxyl to the phosphate derivative 12, followed by lithium ammonia reduction to provide the deoxy-Δ8-THC analogue 13, which in turn was dehydrogenated with sulfur to provide the deoxy-CBN analogue 14 (Scheme ). The various analogues were assayed for binding both to the brain and the peripheral cannabinoid receptors (CB1 and CB2). We have found that the binding profile differs widely between the CBN and the THC series. Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced. Thus, in the CBN series, the selectivity of binding observed with the removal of the hydroxy group is decreased severalfold as compared to what occurs in the THC series. Generally, high affinity for the CB2 receptor was found in analogues when the phenolic hydroxyl was present. The 3-(1‘,1‘-dimethylheptyl) derivatives were found to have much higher affinities than the CBN analogues, which is in complete agreement with previously reported work by Rhee et al.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm0001572</identifier><identifier>PMID: 11020293</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Biological and medical sciences ; Brain - metabolism ; Cannabinoids - metabolism ; Cannabinol - analogs &amp; derivatives ; Cannabinol - chemical synthesis ; Cannabinol - chemistry ; Cannabinol - metabolism ; In Vitro Techniques ; Ligands ; Medical sciences ; Miscellaneous ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Radioligand Assay ; Receptors, Cannabinoid ; Receptors, Drug - metabolism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 2000-10, Vol.43 (20), p.3778-3785</ispartof><rights>Copyright © 2000 American Chemical Society</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a403t-fc0f2bdbb0734bb68b4d372e817f91ff762f65a6d548e5e1d1e9647ca91fe3023</citedby><cites>FETCH-LOGICAL-a403t-fc0f2bdbb0734bb68b4d372e817f91ff762f65a6d548e5e1d1e9647ca91fe3023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm0001572$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm0001572$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1521451$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11020293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahadevan, Anu</creatorcontrib><creatorcontrib>Siegel, Craig</creatorcontrib><creatorcontrib>Martin, Billy R</creatorcontrib><creatorcontrib>Abood, Mary E</creatorcontrib><creatorcontrib>Beletskaya, Irina</creatorcontrib><creatorcontrib>Razdan, Raj K</creatorcontrib><title>Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3, and C-9 positions were chosen since these positions have played a key role in the SAR of THCs. CBN-3-(1‘,1‘-dimethylheptyl) analogues were prepared by sulfur dehydrogenation of Δ8-THC-3-(1‘,1‘-dimethylheptyl) analogues. 9-Substituted CBN analogues were prepared by the standard sulfur dehydrogenation of 9-substituted Δ8-THC analogues (Scheme ), which in turn were prepared following our previous procedure using selenium dioxide oxidation of the corresponding Δ8-THCs followed by sodium chlorite oxidation to give the 9-carboxy-Δ8-THC derivatives. 11-Hydroxy-CBN analogues were prepared from the corresponding 9-carbomethoxy-CBN analogues by reduction with LiAlH4. Deoxy-CBN analogue 14 was prepared from the corresponding Δ8-THC analogue 11 by conversion of the phenolic hydroxyl to the phosphate derivative 12, followed by lithium ammonia reduction to provide the deoxy-Δ8-THC analogue 13, which in turn was dehydrogenated with sulfur to provide the deoxy-CBN analogue 14 (Scheme ). The various analogues were assayed for binding both to the brain and the peripheral cannabinoid receptors (CB1 and CB2). We have found that the binding profile differs widely between the CBN and the THC series. Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced. Thus, in the CBN series, the selectivity of binding observed with the removal of the hydroxy group is decreased severalfold as compared to what occurs in the THC series. Generally, high affinity for the CB2 receptor was found in analogues when the phenolic hydroxyl was present. The 3-(1‘,1‘-dimethylheptyl) derivatives were found to have much higher affinities than the CBN analogues, which is in complete agreement with previously reported work by Rhee et al.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain - metabolism</subject><subject>Cannabinoids - metabolism</subject><subject>Cannabinol - analogs &amp; derivatives</subject><subject>Cannabinol - chemical synthesis</subject><subject>Cannabinol - chemistry</subject><subject>Cannabinol - metabolism</subject><subject>In Vitro Techniques</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Radioligand Assay</subject><subject>Receptors, Cannabinoid</subject><subject>Receptors, Drug - metabolism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0D1PwzAQBmALgWgpDPwBlAGQGAL22YnTgQFSvkQFBYqQWCw7saWUJC52i-DfY9SqXZhueJ87nV6E9gk-JRjI2aTBGJOEwwbqkgRwzDLMNlEXY4AYUqAdtOP9JCBKgG6jDglrGPq0i84f7Jeuo1y2rVRVa-to5KzSPjLWRfkliWRbhglrUZXRsy70dGad30VbRtZe7y1nD71eX43z23j4eHOXXwxjyTCdxabABlSpFOaUKZVmipWUg84IN31iDE_BpIlMy4RlOtGkJLqfMl7IEGqKgfbQ8eLu1NnPufYz0VS-0HUtW23nXnCgQDJKAzxZwMJZ7502YuqqRrofQbD460qsugr2YHl0rhpdruWynAAOl0D6QtbGybao_NolQFhCAosXrPIz_b2KpfsQKac8EePRi3ga0MHoHr-J9-CPFl4WXkzs3LWhun_--wXYMYjo</recordid><startdate>20001005</startdate><enddate>20001005</enddate><creator>Mahadevan, Anu</creator><creator>Siegel, Craig</creator><creator>Martin, Billy R</creator><creator>Abood, Mary E</creator><creator>Beletskaya, Irina</creator><creator>Razdan, Raj K</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001005</creationdate><title>Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors</title><author>Mahadevan, Anu ; Siegel, Craig ; Martin, Billy R ; Abood, Mary E ; Beletskaya, Irina ; Razdan, Raj K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a403t-fc0f2bdbb0734bb68b4d372e817f91ff762f65a6d548e5e1d1e9647ca91fe3023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain - metabolism</topic><topic>Cannabinoids - metabolism</topic><topic>Cannabinol - analogs &amp; derivatives</topic><topic>Cannabinol - chemical synthesis</topic><topic>Cannabinol - chemistry</topic><topic>Cannabinol - metabolism</topic><topic>In Vitro Techniques</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Radioligand Assay</topic><topic>Receptors, Cannabinoid</topic><topic>Receptors, Drug - metabolism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahadevan, Anu</creatorcontrib><creatorcontrib>Siegel, Craig</creatorcontrib><creatorcontrib>Martin, Billy R</creatorcontrib><creatorcontrib>Abood, Mary E</creatorcontrib><creatorcontrib>Beletskaya, Irina</creatorcontrib><creatorcontrib>Razdan, Raj K</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahadevan, Anu</au><au>Siegel, Craig</au><au>Martin, Billy R</au><au>Abood, Mary E</au><au>Beletskaya, Irina</au><au>Razdan, Raj K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2000-10-05</date><risdate>2000</risdate><volume>43</volume><issue>20</issue><spage>3778</spage><epage>3785</epage><pages>3778-3785</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3, and C-9 positions were chosen since these positions have played a key role in the SAR of THCs. CBN-3-(1‘,1‘-dimethylheptyl) analogues were prepared by sulfur dehydrogenation of Δ8-THC-3-(1‘,1‘-dimethylheptyl) analogues. 9-Substituted CBN analogues were prepared by the standard sulfur dehydrogenation of 9-substituted Δ8-THC analogues (Scheme ), which in turn were prepared following our previous procedure using selenium dioxide oxidation of the corresponding Δ8-THCs followed by sodium chlorite oxidation to give the 9-carboxy-Δ8-THC derivatives. 11-Hydroxy-CBN analogues were prepared from the corresponding 9-carbomethoxy-CBN analogues by reduction with LiAlH4. Deoxy-CBN analogue 14 was prepared from the corresponding Δ8-THC analogue 11 by conversion of the phenolic hydroxyl to the phosphate derivative 12, followed by lithium ammonia reduction to provide the deoxy-Δ8-THC analogue 13, which in turn was dehydrogenated with sulfur to provide the deoxy-CBN analogue 14 (Scheme ). The various analogues were assayed for binding both to the brain and the peripheral cannabinoid receptors (CB1 and CB2). We have found that the binding profile differs widely between the CBN and the THC series. Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced. Thus, in the CBN series, the selectivity of binding observed with the removal of the hydroxy group is decreased severalfold as compared to what occurs in the THC series. Generally, high affinity for the CB2 receptor was found in analogues when the phenolic hydroxyl was present. The 3-(1‘,1‘-dimethylheptyl) derivatives were found to have much higher affinities than the CBN analogues, which is in complete agreement with previously reported work by Rhee et al.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>11020293</pmid><doi>10.1021/jm0001572</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2000-10, Vol.43 (20), p.3778-3785
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_72321833
source MEDLINE; American Chemical Society (ACS) Journals
subjects Animals
Biological and medical sciences
Brain - metabolism
Cannabinoids - metabolism
Cannabinol - analogs & derivatives
Cannabinol - chemical synthesis
Cannabinol - chemistry
Cannabinol - metabolism
In Vitro Techniques
Ligands
Medical sciences
Miscellaneous
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Radioligand Assay
Receptors, Cannabinoid
Receptors, Drug - metabolism
Structure-Activity Relationship
title Novel Cannabinol Probes for CB1 and CB2 Cannabinoid Receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A09%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Cannabinol%20Probes%20for%20CB1%20and%20CB2%20Cannabinoid%20Receptors&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Mahadevan,%20Anu&rft.date=2000-10-05&rft.volume=43&rft.issue=20&rft.spage=3778&rft.epage=3785&rft.pages=3778-3785&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm0001572&rft_dat=%3Cproquest_cross%3E72321833%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72321833&rft_id=info:pmid/11020293&rfr_iscdi=true